Ductus Arteriosus in Fetal and Perinatal Life.

J Cardiovasc Dev Dis

Neonatal Intensive Care Unit, Fetal Neonatal and Cardiological Science Research Area, "Bambino Gesù" Children's Hospital, IRCCS, 00165 Rome, Italy.

Published: April 2024

The ductus arteriosus represents an essential vascular structure connecting the pulmonary artery and the aorta. Over the past decades, there has been substantial advancement in our understanding of both the fundamental and clinical aspects of the ductus arteriosus. In particular, the clarification of the regulatory mechanisms governing ductal patency in critical stages such as the fetal and the perinatal period has enabled optimal management of both physiological and pathological conditions in which the ductus arteriosus plays a crucial role. Furthermore, a more in-depth understanding of the regulatory mechanisms controlling this fundamental structure has facilitated the development of advanced therapeutic strategies and personalized interventions. In the present review, we provide a comprehensive overview of the ductus arteriosus during fetal and perinatal life, encompassing its physiological functions, pathological conditions, and clinical implications. Through this examination, we aim to contribute to a broader understanding of the ductus arteriosus' role in these critical developmental stages and its significance in clinical practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050351PMC
http://dx.doi.org/10.3390/jcdd11040113DOI Listing

Publication Analysis

Top Keywords

ductus arteriosus
20
fetal perinatal
12
arteriosus fetal
8
perinatal life
8
regulatory mechanisms
8
pathological conditions
8
ductus
6
life ductus
4
arteriosus
4
arteriosus represents
4

Similar Publications

It was a rare case of a 52-year-old female with a slender PDA combined with PFO related to a transient ischemic attack that did not improve with aspirin and/or clopidogrel treatment. We closed the PDA using the ADO-II occluder and closed the PFO with the occluder, resulting in symptom resolution.

View Article and Find Full Text PDF

Background: Randomized controlled trials (RCTs) have failed to demonstrate the beneficial effects of the pharmacological treatment of patent ductus arteriosus (PDA) in preterm infants. We conducted a Bayesian model averaged (BMA) meta-analysis of RCTs comparing the pharmacological treatment of PDA with placebo or expectant treatment.

Methods: We searched for RCTs including infants with gestational age (GA) ≤ 32 weeks and with a rate of open-label treatment of less than 25% in the control arm.

View Article and Find Full Text PDF

Conjoined twin patients with patent ductus arteriosus and hemodynamic repercussions have a worse prognosis. In the present case report, we demonstrate the first successful percutaneous closure of the ductus arteriosus with the Piccolo© device (Abbot Structural Heart, Plymouth, MN, USA) in this type of clinical situation.

View Article and Find Full Text PDF

Patent Ductus Arteriosus Morphology Changes in Preterm Neonates Undergoing Transcatheter Device Closure.

Pediatr Cardiol

January 2025

Division of Cardiology, Children's Healthcare of Atlanta, Emory University School of Medicine, 2970 Brandywine Rd, Suite 125, Atlanta, GA, 30341, USA.

Evaluate patent ductus arteriosus (PDA) morphology changes in the preterm neonate undergoing transcatheter PDA closure (TCPC). We propose the type F ductus is associated with lower corrected gestational age (CGA) and improved TCPC outcomes. Retrospective review of premature neonates undergoing TCPC at a large volume institution from November 2020 to November 2023.

View Article and Find Full Text PDF

Off-pump Laks-type central shunt for tricuspid atresia with small branch pulmonary arteries.

Multimed Man Cardiothorac Surg

January 2025

• Department of Cardiac Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia • King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia • College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.

Prostaglandin E1 is a potent vasodilator that prevents the ductus arteriosus from closing. Its use in neonates with cyanotic heart defects has revolutionized the management of children with cyanotic heart defects. Although the use of prostaglandin E1 is a temporary solution, the establishment of dependable pulmonary blood flow is of paramount importance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!